Form 4: Twist Bioscience CEO Emily Leproust Executes Stock Transactions to Cover Tax Obligations
Insider Trading Disclosure
Twist Bioscience CEO Emily Leproust sold 2,216 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- Emily Leproust, CEO of Twist Bioscience, sold 2,216 shares of common stock at a price of $52.704 per share on December 6, 2024.
- This sale was not a discretionary trade but was mandated by the company's equity incentive plan to cover tax withholding obligations associated with the vesting of restricted stock units.
- The document also details various employee stock options granted to Ms. Leproust with different vesting schedules and exercise prices.
- These options have vesting dates ranging from September 1, 2016, to October 23, 2029, and exercise prices ranging from $5.95 to $67.85.
- A significant number of shares, 64,950, were also sold to cover tax obligations related to performance stock options that vested on December 19, 2022.
Sentiment
Score: 5
Explanation: The document is neutral, detailing routine stock transactions for tax purposes. It does not indicate any positive or negative sentiment.
Positives
- The document provides transparency regarding the CEO's stock transactions.
- The vesting schedules of the stock options are clearly outlined.
Risks
- The sale of shares by the CEO, even for tax purposes, could be perceived negatively by some investors.
- The complexity of the stock option vesting schedules could be difficult for some investors to understand.
Industry Context
This type of stock transaction is common for executives who receive stock-based compensation. It is a routine part of managing personal finances and tax obligations.
Comparison to Industry Standards
- Many biotech and technology companies use stock options and restricted stock units as part of their compensation packages.
- The vesting schedules and tax withholding practices described are typical for companies in this sector.
- Similar transactions are regularly reported by executives at companies like Illumina, Agilent, and Thermo Fisher Scientific.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on the stock price, but it is unlikely to be significant given the nature of the transaction.
- The document provides transparency to shareholders regarding the CEO's stock transactions.
Key Dates
| Date | Description |
|---|---|
| 2016-09-01 | 25% of shares subject to one option vested on this date, with the remainder vesting monthly. |
| 2017-09-28 | 10% of shares subject to one option vested on this date, with additional vesting on subsequent anniversaries. |
| 2018-09-28 | 15% of shares subject to one option vested on this date, with additional vesting on subsequent anniversaries. |
| 2019-10-31 | 20% of shares subject to one option vested on this date, with the remainder vesting monthly. |
| 2020-09-01 | Performance stock options granted to the reporting person on this date. |
| 2020-10-24 | 25% of shares subject to one option vested on this date, with the remainder vesting monthly. |
| 2022-12-19 | Performance stock options vested and became exercisable on this date. |
| 2024-12-06 | Emily Leproust sold 2,216 shares of common stock. |
| 2024-12-10 | Date of signature by Attorney-in-Fact for Emily M. Leproust. |
| 2025-09-28 | Date of one of the employee stock options. |
| 2027-09-28 | Date of one of the employee stock options. |
| 2028-11-18 | Date of one of the employee stock options. |
| 2029-10-23 | Date of one of the employee stock options. |
| 2030-08-31 | Date of one of the employee stock options. |
Keywords
Twist Bioscience, TWST, Emily Leproust, stock options, restricted stock units, tax withholding, equity incentive plans, insider trading, vesting, performance stock options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.